H pylori regimen
Reading File
Finding Sources
Searching PubMed
"Helicobacter pylori" AND eradication AND treatment
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive data from Harrison's and Yamada's to construct a thorough answer.
H. pylori Eradication Regimens
Who to Treat
Eradication is indicated in:
- Peptic ulcer disease (active or past) - regardless of NSAID use
- Gastric MALT lymphoma (60-90% achieve complete remission)
- After resection of early gastric cancer
- Uninvestigated dyspepsia (ACG: age <60 years; test-and-treat if local prevalence >20%)
- First-degree relatives of gastric cancer patients
- Long-term NSAID users (especially with prior PUD history)
- Unexplained vitamin B12 deficiency
First-Line Regimens
The choice depends on local clarithromycin resistance rates (<15% = low, >15% = high) and prior macrolide exposure.
1. Clarithromycin Triple Therapy
Use only if clarithromycin resistance <15% AND no prior macrolide exposure
| Drug | Dose | Frequency |
|---|---|---|
| PPI (any standard dose) | Omeprazole 20 mg / Pantoprazole 40 mg / Esomeprazole 40 mg / Lansoprazole 30 mg / Rabeprazole 20 mg | BID |
| Clarithromycin | 500 mg | BID |
| Amoxicillin | 1 g | BID |
| (Or metronidazole 500 mg TID if penicillin allergy) |
Duration: 14 days | Eradication rate: 75-90%
2. Bismuth Quadruple Therapy (BQT)
Now often recommended as first-line, particularly where clarithromycin resistance is high
| Drug | Dose | Frequency |
|---|---|---|
| PPI | Standard dose | BID |
| Bismuth subcitrate | 120-300 mg | QID |
| (or Bismuth subsalicylate) | 300 mg | QID |
| Tetracycline | 500 mg | QID |
| Metronidazole | 250-500 mg | QID/TID |
Duration: 10-14 days | Eradication rate: 85-90%
3. Concomitant (Non-bismuth) Quadruple Therapy
Alternative when bismuth unavailable; all 4 drugs given simultaneously
| Drug | Dose | Frequency |
|---|---|---|
| PPI | Standard dose | BID |
| Clarithromycin | 500 mg | BID |
| Amoxicillin | 1 g | BID |
| Metronidazole/Tinidazole | 500 mg | BID |
Duration: 10-14 days | Eradication rate: ~90%
4. Sequential Therapy (alternative non-bismuth quadruple)
- Days 1-5: PPI + Amoxicillin 1 g BID
- Days 6-10: PPI + Clarithromycin 500 mg + Metronidazole 500 mg (all BID)
5. Hybrid Therapy (alternative)
- Days 1-7: PPI + Amoxicillin 1 g BID
- Days 8-14: PPI + Amoxicillin 1 g + Clarithromycin 500 mg + Metronidazole 500 mg (all BID)
Second-Line (Salvage) Regimens
If initial eradication fails, avoid re-using clarithromycin if it was used first-line.
| Regimen | Drugs | Duration |
|---|---|---|
| Levofloxacin triple | PPI + Levofloxacin 500 mg + Amoxicillin 1 g (all BID) | 10 days |
| Bismuth quadruple (if not used 1st line) | PPI + Bismuth + Tetracycline + Metronidazole | 10-14 days |
| Rifabutin triple | PPI + Rifabutin 150 mg + Amoxicillin 1 g (BID) | 10 days - ~86% cure in resistant strains |
Third-line: Culture and sensitivity testing strongly recommended before choosing agents.
Key Points
- 14 days outperforms 7-10 days; do not shorten
- Clarithromycin resistance is the #1 cause of treatment failure - rates >50% in some countries
- Metronidazole resistance is common (30% in North America, up to 80% in developing countries) but triple therapy still achieves >50% eradication even with resistant strains
- Amoxicillin and tetracycline resistance remain rare (<1-2%)
- Confirm eradication with urea breath test or stool antigen at least 4 weeks after completing treatment and 2 weeks after stopping PPI
- Probiotics as adjunct may reduce antibiotic-related side effects
- Side effects affect 20-30% of patients on triple therapy
Antibiotic Selection Summary by Resistance Context
| Clarithromycin Resistance | Recommended First-Line |
|---|---|
| Low (<15%), no prior macrolides | Clarithromycin triple (14 days) OR bismuth quadruple |
| High (>15%) or unknown | Bismuth quadruple (first choice) or concomitant quadruple |
| Metronidazole also high | Bismuth + tetracycline + alternative antibiotic |
Sources: Harrison's Principles of Internal Medicine 22E (2025), pp. 2570-2571; Yamada's Textbook of Gastroenterology 7e, Chapter 49
Recent evidence note: A 2025 meta-analysis (PMID 39824392) confirms eradication therapy significantly reduces gastric cancer risk. A 2024 AGA expert review (PMID 39269391) also highlights potassium-competitive acid blockers (P-CABs) as emerging alternatives to PPIs in H. pylori regimens, potentially improving acid suppression and eradication rates.
This is a shared conversation. Sign in to Orris to start your own chat.